1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Beijing Tong Ren Tang Chinese Medicine Company Limited

Beijing Tong Ren Tang Chinese Medicine Company Limited

BJTRF
Beijing Tong Ren Tang Chinese Medicine Company LimitedUS flagOther OTC
0.65
USD
- -
- -
542.78MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.82
0.92
1.16
1.3
1.51
1.81
1.71
1.57
1.86
2.07
1.82
1.93
1.81
1.67
Basic EPS, GAAP
0.29
0.35
0.42
0.5
0.59
0.69
0.66
0.65
0.73
0.77
0.65
0.6
0.47
0.65
Free Cash Flow per Basic Share
0.02
0.21
0.39
0.51
0.52
0.63
0.64
0.12
0.9
0.61
0.52
-0.31
0.94
- -
Dividend per Share
0.13
0.08
0.1
0.13
0.16
0.19
0.95
0.23
0.24
0.53
0.33
0.33
0.35
- -
Book Value per Share
1.1
1.8
2.2
2.57
2.99
3.49
3.21
3.63
4.11
4.35
4.67
4.94
5.06
3.17
Tangible Book Value per Share
1.75
1.85
2.21
2.56
3.02
3.53
3.23
3.67
4.16
4.4
4.74
4.99
5.14
3.19
Basic Weighted Avg Shares
749
830
836
837
837
837
837
837
837
837
837
837
837
837
Sales/Revenue/Turnover
614
761
970
1,084
1,266
1,514
1,433
1,315
1,556
1,731
1,525
1,612
1,513
1,402
Operating Margin (%)
40.79
44.94
46.25
48.29
47.05
46.04
45.35
51
50.32
47.1
41.89
35.61
35.39
46.92
Depreciation Expense
15
18
23
24
27
31
79
78
70
75
83
88
98
- -
Net Income, GAAP
220
287
354
420
490
581
556
542
608
646
540
500
397
540
Effective Tax Rate (%)
16.18
17.04
17.97
17.36
17.26
16.59
16.3
17.21
16.3
16.3
14.13
15.97
17.4
17.16
Profit Margin (%)
35.83
37.73
36.5
38.76
38.7
38.36
38.82
41.24
39.06
37.31
35.44
31.04
26.25
38.53
Working Capital
1,062
1,229
1,541
1,834
2,207
2,606
2,337
2,716
3,064
3,264
3,514
3,730
3,858
2,316
LT Debt
- -
- -
1
1
1
1
60
65
75
61
75
66
74
1
Total Equity
1,310
1,537
1,909
2,227
2,608
3,024
2,766
3,130
3,540
3,739
4,021
4,246
4,369
2,748
Return on Invested Capital (%)
21.94
19.61
21.03
20.57
20.1
20.44
18.02
17.77
18.86
17.84
13.54
11.36
10.09
20.71
Return on Capital (%)
29.77
23.19
19.19
19.15
19.47
19.77
18.15
16.94
16.35
15.95
12.26
11.06
8.52
20.26
Return on Common Equity (%)
33.37
24.71
21.24
21.08
21.06
21.39
19.82
18.96
18.76
18.22
14.31
12.44
9.49
21.94

Capital Structure

FRC

•

in mil. unless spec.
Dec'17
Mar'18
Jun'18
ST Debt
- -
- -
- -
LT Borrowings
1
- -
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
837
- -
837
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'17
Mar'18
Jun'18
Total Current Assets
2,355
- -
2,526
Cash, Cash Equivalents & STI
1,898
- -
1,971
Accounts Receivable, Net
171
- -
216
Inventories
236
- -
289
Total Current Liabilities
147
- -
210
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.91%
6.95%
2.88%
Free Cash Flow
-0.33%
4.45%
-402.72%
Net Income, GAAP
2.1%
-5.21%
-20.6%
Sales/Revenue/Turnover
5.17%
3.45%
-6.1%
Total Cash Common Dividend
- -
- -
6.06%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1,525
2024
- -
- -
- -
- -
1,612
2025
- -
- -
- -
- -
1,513

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.65
2024
- -
- -
- -
- -
0.6
2025
- -
- -
- -
- -
0.47

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.33
2024
- -
- -
- -
- -
0.33
2025
- -
- -
- -
- -
0.35

Company Description

APIChat
CEO
Wang Chi
Full Time Employees
782
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
Office Tower Wan Chai Hong Kong
IPO Date
Apr 19, 2021
Website
tongrentangcm.com
Similar Companies
Fabino Enterprises Ltd (FABINO.BO)
Sundrug Co.,Ltd. (SDGCF)
Leafly Holdings, Inc. (LFLY)
Tsubota Laboratory Incorporated (4890.T)
Cellyan Biotechnology Co., Ltd (HKPD)
Allstar Health Brands, Inc. (ALST)
Business
Beijing Tong Ren Tang Chinese Medicine Company Limited specializes in the manufacture, retail, and wholesale of traditional Chinese medicine (TCM) and healthcare products. Its core product portfolio comprises proprietary Chinese medicines, such as the flagship Angong Niuhuang Pill, Ganoderma Lucidum (Lingzhi) products, and various health supplements including herbal teas and capsules. The company also provides Chinese medical consultation and treatment services through its retail outlets. Operating across three main geographic segments—Mainland China, Hong Kong, and overseas markets—it maintains around 140 branches in over 29 countries and regions, including Asia, Oceania, North America, and Europe. Founded in 1669 and headquartered in Wan Chai, Hong Kong, Beijing Tong Ren Tang leverages a heritage of over 350 years in medicinal product development combined with modern innovation and research investment focusing on product efficacy, safety, and quality certification standards. Recent major developments include significant leadership changes in 2025, with new appointments to the board and executive management roles enhancing corporate governance. The company has embarked on strategic expansion by increasing retail outlets internationally, targeting 50 new stores in Europe and North America to capitalize on the growing global demand for TCM. In addition, Beijing Tong Ren Tang has strengthened its research and development capabilities by allocating substantial investment toward innovating new formulations and integrating modern scientific methods with traditional herbal medicine. It reported record sales growth with a revenue increase of over 12% in recent financial years, driven by expanded international sales constituting over 40% of total revenue and a stronger focus on e-commerce platforms. Sustainability and community health initiatives also form part of its recent strategic focus. Beijing Tong Ren Tang's broad product range, beyond proprietary medicines, includes health supplements, dietary aids, and wellness products marketed under the Tong Ren Tang brand. The company follows a rigorous quality control system aligning with GMP and ISO certifications to uphold its reputation for high standards. This comprehensive approach, combined with its historical legacy and a global market presence, positions Beijing Tong Ren Tang as a leading player in the traditional medicine sector with a clear emphasis on modernization, international expansion, and holistic healthcare solutions.